Review



adrb2 polyclonal ab  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bioss adrb2 polyclonal ab
    Adrb2 Polyclonal Ab, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adrb2 polyclonal ab/product/Bioss
    Average 94 stars, based on 4 article reviews
    adrb2 polyclonal ab - by Bioz Stars, 2026-05
    94/100 stars

    Images



    Similar Products

    adrb2 polyclonal ab  (Bioss)
    94
    Bioss adrb2 polyclonal ab
    Adrb2 Polyclonal Ab, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adrb2 polyclonal ab/product/Bioss
    Average 94 stars, based on 1 article reviews
    adrb2 polyclonal ab - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    β2 ar  (Elabscience Biotechnology)
    90
    Elabscience Biotechnology β2 ar
    Fig. 2. Relative mRNA expression of cardiac β1-AR, <t>β2-AR,</t> GRK2, and GRK3 in rats treated with P. Note a statistically significant decrease of GRK2 mRNA levels in rats treated with paroxetine, 10 mg/kg/day p.o. Data represent the mean of five rats ± SEM. *p < 0.05 vs. control group (One-way ANOVA fol lowed by Tukey’s multiple comparisons). β-AR, beta-adrenergic receptor; GRK, G protein-coupled receptor kinase.
    β2 Ar, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/β2 ar/product/Elabscience Biotechnology
    Average 90 stars, based on 1 article reviews
    β2 ar - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    adrb2 polyclonal ab, fitc conjugated (h- 20)  (Bioss)
    90
    Bioss adrb2 polyclonal ab, fitc conjugated (h- 20)
    Fig. 2. Relative mRNA expression of cardiac β1-AR, <t>β2-AR,</t> GRK2, and GRK3 in rats treated with P. Note a statistically significant decrease of GRK2 mRNA levels in rats treated with paroxetine, 10 mg/kg/day p.o. Data represent the mean of five rats ± SEM. *p < 0.05 vs. control group (One-way ANOVA fol lowed by Tukey’s multiple comparisons). β-AR, beta-adrenergic receptor; GRK, G protein-coupled receptor kinase.
    Adrb2 Polyclonal Ab, Fitc Conjugated (H 20), supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adrb2 polyclonal ab, fitc conjugated (h- 20)/product/Bioss
    Average 90 stars, based on 1 article reviews
    adrb2 polyclonal ab, fitc conjugated (h- 20) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 2. Relative mRNA expression of cardiac β1-AR, β2-AR, GRK2, and GRK3 in rats treated with P. Note a statistically significant decrease of GRK2 mRNA levels in rats treated with paroxetine, 10 mg/kg/day p.o. Data represent the mean of five rats ± SEM. *p < 0.05 vs. control group (One-way ANOVA fol lowed by Tukey’s multiple comparisons). β-AR, beta-adrenergic receptor; GRK, G protein-coupled receptor kinase.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.

    doi: 10.1016/j.biopha.2021.112411

    Figure Lengend Snippet: Fig. 2. Relative mRNA expression of cardiac β1-AR, β2-AR, GRK2, and GRK3 in rats treated with P. Note a statistically significant decrease of GRK2 mRNA levels in rats treated with paroxetine, 10 mg/kg/day p.o. Data represent the mean of five rats ± SEM. *p < 0.05 vs. control group (One-way ANOVA fol lowed by Tukey’s multiple comparisons). β-AR, beta-adrenergic receptor; GRK, G protein-coupled receptor kinase.

    Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200), β2-AR (Elabscience®, ADRB2 polyclonal antibody, dilution 1:200), GRK2 (Elabscience®, GRK2 polyclonal antibody, dilution 1:300), and GRK3 (Elabscience®, GRK3 polyclonal antibody, dilution 1:300).

    Techniques: Expressing, Control

    Fig. 6. Representative photomicrographs of immunohistochemical analysis showing β1-AR and β2-AR. Note decreased immunoreactivity in DOX+P rats. β-AR, beta- adrenergic receptor; DOX, doxorubicin; P, paroxetine.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.

    doi: 10.1016/j.biopha.2021.112411

    Figure Lengend Snippet: Fig. 6. Representative photomicrographs of immunohistochemical analysis showing β1-AR and β2-AR. Note decreased immunoreactivity in DOX+P rats. β-AR, beta- adrenergic receptor; DOX, doxorubicin; P, paroxetine.

    Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200), β2-AR (Elabscience®, ADRB2 polyclonal antibody, dilution 1:200), GRK2 (Elabscience®, GRK2 polyclonal antibody, dilution 1:300), and GRK3 (Elabscience®, GRK3 polyclonal antibody, dilution 1:300).

    Techniques: Immunohistochemical staining

    Fig. 7. Relative mRNA expression of cardiac β-1 AR, β-2 AR, GRK2, GRK3, ARRB1, and ARRB2 in DOX- and DOX+P -treated rats. Note a statistically significant increase of GRK2 and GRK3 mRNA levels in DOX-HCM rats, a statistically significant increase of β1-AR and β2-AR mRNA levels, and a statistically significant decrease of GRK2 and GRK3 mRNA levels in DOX+P-treated rats. Data represent the mean of at least 7 rats ± SEM.*p < 0.05; * *p < 0.01 vs. control group, †p < 0.05; ††p < 0.01 vs. DOX-HCM, #p < 0.05; ##p < 0.01 vs. DOX-DCM (One-way ANOVA followed by Tukey’s multiple comparisons or Kruskal–Wallis ANOVA followed by Mann–Whitney U test for nonparametric data). β-AR, beta-adrenergic receptor; DCM, dilated cardiomyopathy; DOX, doxorubicin; HCM, hypertrophic cardiomy opathy; GRK, G protein-coupled receptor kinase; P, paroxetine.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.

    doi: 10.1016/j.biopha.2021.112411

    Figure Lengend Snippet: Fig. 7. Relative mRNA expression of cardiac β-1 AR, β-2 AR, GRK2, GRK3, ARRB1, and ARRB2 in DOX- and DOX+P -treated rats. Note a statistically significant increase of GRK2 and GRK3 mRNA levels in DOX-HCM rats, a statistically significant increase of β1-AR and β2-AR mRNA levels, and a statistically significant decrease of GRK2 and GRK3 mRNA levels in DOX+P-treated rats. Data represent the mean of at least 7 rats ± SEM.*p < 0.05; * *p < 0.01 vs. control group, †p < 0.05; ††p < 0.01 vs. DOX-HCM, #p < 0.05; ##p < 0.01 vs. DOX-DCM (One-way ANOVA followed by Tukey’s multiple comparisons or Kruskal–Wallis ANOVA followed by Mann–Whitney U test for nonparametric data). β-AR, beta-adrenergic receptor; DCM, dilated cardiomyopathy; DOX, doxorubicin; HCM, hypertrophic cardiomy opathy; GRK, G protein-coupled receptor kinase; P, paroxetine.

    Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200), β2-AR (Elabscience®, ADRB2 polyclonal antibody, dilution 1:200), GRK2 (Elabscience®, GRK2 polyclonal antibody, dilution 1:300), and GRK3 (Elabscience®, GRK3 polyclonal antibody, dilution 1:300).

    Techniques: Expressing, Control, MANN-WHITNEY